1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 138,00 | 141,00 | 07.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target | 1 | Investing.com | ||
| 03.12.25 | Belite Bio stock price target raised to $187 from $132 at Benchmark | 3 | Investing.com | ||
| 02.12.25 | Mizuho upgrades Belite Bio stock to Outperform on positive trial data | 1 | Investing.com | ||
| 02.12.25 | Mizuho stuft Belite Bio nach positiven Studiendaten auf 'Outperform' hoch | 8 | Investing.com Deutsch | ||
| 02.12.25 | Belite Bio prices 2.27M ADSs at $154.00 to raise $350M in public offering | 2 | Seeking Alpha | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 02.12.25 | Belite Bio prices public offering of ADSs at $154 each | 1 | Investing.com | ||
| 02.12.25 | Belite Bio, Inc: Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Why Belite Bio Stock Soared on Monday | 1 | The Motley Fool | ||
| 01.12.25 | Belite Bio kündigt Kapitalerhöhung an - Aktie gibt nach | 2 | Investing.com Deutsch | ||
| 01.12.25 | Belite Bio launches public offering of American Depositary Shares | 1 | Investing.com | ||
| 01.12.25 | Belite Bio announces proposed underwritten public offering of ADSs | 1 | Seeking Alpha | ||
| 01.12.25 | Belite Bio, Inc: Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares | 1 | GlobeNewswire (USA) | ||
| 01.12.25 | Belite continues ascent as Stargardt drug hits mark in late-stage trial | 2 | BioPharma Dive | ||
| 01.12.25 | Belite Bio Reports Landmark Phase 3 Success For Tinlarebant In Stargardt Disease | - | RTTNews | ||
| 01.12.25 | Belite brings FDA filing into view with phase 3 Stargardt disease victory | 1 | FierceBiotech | ||
| 01.12.25 | Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease | 1 | Benzinga.com | ||
| 01.12.25 | Belite plans filing for oral Stargardt drug after phase 3 win | 1 | pharmaphorum | ||
| 01.12.25 | Belite Bio's tinlarebant shows 36% reduction in Stargardt disease lesions | 1 | Investing.com | ||
| 01.12.25 | Belite Bio meldet Erfolg in Phase-3-Studie: Tinlarebant reduziert Läsionen bei Morbus Stargardt um 36 % | 2 | Investing.com Deutsch | ||
| 01.12.25 | Belite Bio, Inc: New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease | 2 | GlobeNewswire (USA) |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,397 | +3,49 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| ARGENX | 699,00 | +1,48 % | Argenx Names Karen Massey As CEO, Tim Van Hauwermeiren To Become Board Chairman | BRUSSELS (dpa-AFX) - argenx SE (ARGX), an immunology company, on Monday announced that Karen Massey, the company's current Chief Operating Officer, will transition to Chief Executive Officer... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation Officer | The newly created role marks a major step in CEO Kenneth Bilenberg's vision to scale Avid for its next chapter of growth.
TUSTIN, Calif., Nov. 10, 2025 /PRNewswire/... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,540 | +1,99 % | Protalix stellt Strategie 2026 vor: Fokus auf Gichttherapie und seltene Nierenerkrankungen | ||
| ENZO BIOCHEM | 0,388 | 0,00 % | Battery Ventures Completes Take-Private of Enzo Biochem | Apter joins as CEO to support the next stage of growth for the life-science reagents platform
BOSTON--(BUSINESS WIRE)--Battery Ventures, a global, technology-focused investment firm, announced the... ► Artikel lesen | |
| QUANTERIX | 6,625 | +1,07 % | Quanterix Corporation: Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence | Simoa p-Tau 217 Assay Enables Largest Population-Based Assessment (11,000+ Samples) Revealing Striking Age-Related Increase and Broad Treatment Eligibility
Quanterix Corporation(NASDAQ: QTRX),... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 10,020 | +5,36 % | Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights | FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 23,280 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| NUVALENT | 106,82 | +9,78 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,730 | 0,00 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,270 | +4,28 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| ERASCA | 5,170 | 0,00 % | Piper Sandler stuft Erasca mit "Overweight" ein - Kursziel bei 5 US-Dollar | ||
| ALUMIS | 17,920 | 0,00 % | Should You Chase the Rally in Alumis Stock Today? | ||
| AVIDITY BIOSCIENCES | 72,37 | +0,21 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 76,69 | +4,41 % | Wolfe Research stuft Kymera Therapeutics wegen fehlender Impulse herab |
BELITE BIO INC ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 139,00 Euro und damit +2,21 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.